Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Duolingo Inc (DUOL) vs Eli Lilly And Co (LLY) Price & Performance

Duolingo IncTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Duolingo Inc vs Eli Lilly And Co — how do they compare? Duolingo Inc trades at $130.45 (market cap $5.98B), while Eli Lilly And Co trades at $1,156.7 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 172.2× Duolingo Inc's market cap, and Eli Lilly And Co pays a 0.6% dividend while Duolingo Inc pays none. Which is the better fit depends on your goals.

DUOLLLY
Market Cap
$5.98B$1.03T
Sector
TechnologyHealth
52-Week High
$390.84$1.24K
52-Week Low
$90.03$625.65
Enterprise Value
$4.82B$1.07T
Dividend Yield
0.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Duolingo Inc

Duolingo (DUOL) trades at $132.34, up 6.08% in the last session, reflecting strong momentum. The stock shows bullish technical signals with support at $127 and resistance at $135. Fundamentally, revenue grew to $1.04 billion in 2025, with net income surging to $414 million, driven by robust user engagement and AI feature expansion. Recent earnings beats and a positive analyst consensus highlight investor confidence in the company's growth trajectory.

Outlook remains positive with AI-driven user growth and profitability, but risks include rising inference costs and competitive pressures. The stock offers growth potential, yet investors should monitor margin trends and market volatility. Analyst price targets suggest moderate upside from current levels, with a consensus of $108.29.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,185.08, down slightly (-0.29%) on the day, with a strong bullish technical signal from moving averages. The company demonstrates exceptional fundamental strength, with revenue surging to $65.18B in 2025 and a net income margin of 34.99%. Recent earnings have consistently beaten expectations, and analyst sentiment is overwhelmingly positive, with a consensus price target of $1,360.

The outlook for LLY remains robust, driven by its dominant position in the high-growth weight loss and Alzheimer's drug markets. Key opportunities include continued revenue expansion and pipeline advancements. Primary risks involve intensifying competition, particularly from Novo Nordisk's obesity pill, and the stock's premium valuation multiples, which demand sustained high growth to justify.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Duolingo Inc

Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue

Read more on DUOL

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY